Inventor · disambiguated record
Hiroshi Shiku
Also filed as: SHIKU HIROSHI
23 granted patents·20 pending applications·416 citations·filing 1997–2025
94Inventor score
Top patents by PatentIndex Score
43 records- 0196US8586023B2Cell capable of expressing exogenous GITR ligandSHIKU HIROSHI·Filed 2009·Granted Nov 19, 2013·317 cites·8 claims
- 0291US9175308B2Chimeric antigen receptorUNIV MIE·Filed 2012·Granted Nov 3, 2015·35 cites·8 claims
- 0388US9051391B2Method for expression of specific geneMINENO JUNICHI·Filed 2008·Granted Jun 9, 2015·26 cites·5 claims
- 0484US11497768B2Antigen-binding protein that recognizes MAGE-A4-derived peptideUNIV MIE·Filed 2018·Granted Nov 15, 2022·3 cites·20 claims
- 0580US9181525B2Method for enhancing a function of a T cellSHIKU HIROSHI·Filed 2010·Granted Nov 10, 2015·3 cites·12 claims
- 0680US8003770B2T-cell receptor and nucleic acid encoding the receptorUNIV MIE·Filed 2006·Granted Aug 23, 2011·5 cites·16 claims
- 0778US8383401B2T-cell receptor and nucleic acid encoding the receptorUNIV MIE·Filed 2011·Granted Feb 26, 2013·4 cites·20 claims
- 0876US11952423B2Bispecific antibodyUNIV MIE·Filed 2023·Granted Apr 9, 2024·0 cites·28 claims
- 0975US8951510B2T-cell receptor and nucleic acid encoding the receptorUNIV MIE·Filed 2013·Granted Feb 10, 2015·3 cites·10 claims
- 1073US9603874B2Method for enhancing a function of a T cellUNIV MIE·Filed 2015·Granted Mar 28, 2017·1 cites·11 claims
- 1172US11714068B2Exosome production methodUNIV MIE·Filed 2019·Granted Aug 1, 2023·1 cites·6 claims
- 1272US2025282889A1Bispecific antibodyUNIV MIE·Filed 2025·Application pending·0 cites
- 1368US11083744B2Therapeutic agent associated with suppression of proliferation and metastasis of tumor, which comprises exosomes released from cytotoxic T cells and targets cancer stromal/mesenchymal cellsUNIV MIE·Filed 2016·Granted Aug 10, 2021·1 cites·13 claims
- 1468US9296807B2Method for expression of specific geneTAKARA BIO INC·Filed 2015·Granted Mar 29, 2016·1 cites·2 claims
- 1567US9243227B2Cytotoxic T lymphocyteSHIKU HIROSHI·Filed 2012·Granted Jan 26, 2016·1 cites·11 claims
- 1667US2022062398A1Long chain antigen containing interepitope sequence that promotes antigen presentation to t cellsUNIV MIE·Filed 2021·Application pending·0 cites
- 1766US12344674B2Bispecific antibodyUNIV MIE·Filed 2021·Granted Jul 1, 2025·0 cites·18 claims
- 1866US11179450B2Long chain antigen containing interepitope sequence that promotes antigen presentation to T cellsUNIV MIE·Filed 2018·Granted Nov 23, 2021·0 cites·23 claims
- 1963US7414032B2Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTLIMMUNOFRONTIER INC·Filed 2003·Granted Aug 19, 2008·1 cites·16 claims
- 2062US9144603B2Cell capable of expressing exogenous GITR ligandUNIV MIE·Filed 2013·Granted Sep 29, 2015·0 cites·7 claims
- 2162US2009246213A1Vaccine comprising a polynucleotide encoding an antigen recognized by a cd4+ helper t-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a cd8+ ctlIMMUNOFRONTIER INC·Filed 2008·Application pending·0 cites
- 2261US2025339460A1Hyaluronic acid derivative, pharmaceutical composition, and method for producing pharmaceutical compositionASAHI CHEMICAL IND·Filed 2023·Application pending·0 cites
- 2360US8168191B2Cytotoxic T lymphocyteSHIKU HIROSHI·Filed 2008·Granted May 1, 2012·0 cites·2 claims
- 2459US2009136446A1Induction of regulatory t cell-resistant helper cd4+ t cellsLUDWIG INST FOR CANCER RES LTD·Filed 2008·Application pending·0 cites
- 2558US2010247579A1Therapeutic agent for cancerSHIKU HIROSHI·Filed 2008·Application pending·0 cites
- 2657US2024024480A1Prame binding moleculeUNIV MIE·Filed 2021·Application pending·0 cites
- 2755US2024398864A1Pharmaceutical compositionUNIV MIE·Filed 2022·Application pending·0 cites
- 2854US2016367651A1T cell inducing vaccine containing an interepitope sequence that promotes antigen presentationUNIV MIE·Filed 2014·Application pending·0 cites
- 2952US6656481B1Vaccinal preparationsMITSUBISHI CHEM CORP·Filed 1997·Granted Dec 2, 2003·14 cites·56 claims
- 3052US2022265717A1Antigen receptorUNIV MIE·Filed 2020·Application pending·0 cites
- 3152US2008166369A1Cancer Vaccine PreparationIMMUNO FRONTIER INC·Filed 2005·Application pending·0 cites
- 3251US2022275104A1Gd2 binding moleculeUNIV MIE·Filed 2020·Application pending·0 cites
- 3351US2021161963A1Method for gene transfer into gamma-delta type t cellUNIV MIE·Filed 2019·Application pending·0 cites
- 3450US2006073126A1Cytotoxic T lymphocyteTAKARA BIO INC·Filed 2005·Application pending·0 cites
- 3549US11213538B2Agent for overcoming immunosuppression and use thereofGENERAL INCORPORATED ASS PHARMA VALLEY PROJECT SUPPORTING ORGANIZATION·Filed 2017·Granted Jan 4, 2022·0 cites·4 claims
- 3647US2005244412A1Method and composition for regulating activity of regulatory T cellsSHIKU HIROSHI·Filed 2005·Application pending·0 cites
- 3747US2006121029A1Method and composition for regulating the activity of regulatory t cellsSHIKU HIROSHI·Filed 2002·Application pending·0 cites
- 3847US2019111078A1Pretreatment drug for t cell infusion therapy for immune-checkpoint inhibitor-resistant tumorUNIV MIE·Filed 2017·Application pending·0 cites
- 3946US2022160849A1Cancer vaccine formulationUNIV MIE·Filed 2020·Application pending·0 cites
- 4044US2006182721A1Method of preparing langerhans cell from cd14-positive cell being human peripheral blood mononuclear cell with use of notch ligand delta-1, gm-csf and tgf-ssKIRIN BEER KABSHIKI KAISHA·Filed 2004·Application pending·0 cites
- 4143US12479901B2T-cell receptorUNIV MIE·Filed 2019·Granted Nov 25, 2025·0 cites·3 claims
- 4243US11039908B2Needleless syringe and method for introducing DNA into injection target area using sameUNIV MIE·Filed 2016·Granted Jun 22, 2021·0 cites·7 claims
- 4338US2014322344A1Vaccine preparation for cancer treatmentSHIKU HIROSHI·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Hiroshi Shiku files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →